Is Ozempic a Tablet or Injection? Understanding Its Use for Weight Loss

Last reviewed: July 1, 2026

Last updated: July 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic is both — and neither form is approved for weight loss. That two-part answer is the one most articles get wrong, because the landscape changed. Ozempic began as a once-weekly subcutaneous injection, and it still is one. But there is now also an Ozempic tablet: the FDA labeling for RYBELSUS and OZEMPIC tablets covers oral semaglutide in 1.5 mg, 4 mg, and 9 mg tablet strengths under the Ozempic name. What has not changed is the indication. Every approved form of Ozempic, injectable or oral, is a type 2 diabetes medication. If you are looking for semaglutide approved for weight management, the brand you are looking for is Wegovy.

Ozempic Exists in Two Dosage Forms Now

The injection came first. According to the Ozempic prescribing information, it is supplied as multi-dose pens delivering 2 mg/3 mL, 4 mg/3 mL, and 8 mg/3 mL, along with prefilled single-dose syringes of 0.25 mg, 0.5 mg, or 1 mg per 0.5 mL. It is given subcutaneously once weekly.

The tablet arrived through a different application. Its labeling is shared with Rybelsus, the original oral semaglutide product, and covers Rybelsus at 3 mg, 7 mg, and 14 mg alongside Ozempic tablets at 1.5 mg, 4 mg, and 9 mg. So the honest answer to "tablet or injection" is that the Ozempic name now sits on both, and the two are not interchangeable in strength — the milligram numbers on an oral tablet and an injectable pen are not measuring the same thing, because absorption from the gut is a fraction of what a subcutaneous injection delivers.

What Ozempic Is Actually Approved to Treat

The Ozempic injection label lists three indications: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

The tablet label is narrower still. RYBELSUS and OZEMPIC tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events.

Read those lists again and notice what is missing. There is no obesity indication, no overweight indication, and no body mass index eligibility criterion anywhere in the Ozempic labeling. A drug's indication is a regulatory statement about the population and purpose the FDA reviewed evidence for. Weight loss is a documented pharmacologic effect of semaglutide; it is not part of what Ozempic is approved to do.

Wegovy Is the Semaglutide Brand Approved for Weight Management

Same molecule, different application, different label. The Wegovy prescribing information indicates the injection, in combination with a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity, or adults with overweight plus at least one weight-related comorbid condition; and for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.

Wegovy also now exists in both forms. The injection is supplied at 0.25, 0.5, 1, 1.7, 2.4, and 7.2 mg per dose, the last of these being Wegovy HD. Wegovy tablets come in 1.5, 4, 9, and 25 mg strengths, and carry two of the injection's indications — cardiovascular risk reduction and weight reduction in adults — without the pediatric or liver-disease indications.

Why the Confusion Is So Persistent

Three things collided. Ozempic reached cultural saturation before Wegovy did, so the brand name became shorthand for the entire drug class. The active ingredient genuinely is the same in both. And people with type 2 diabetes taking Ozempic really do lose weight, which makes the informal association feel confirmed by experience.

But approval follows an application, not a chemical. Novo Nordisk submitted a diabetes program and an obesity program separately, each with its own trials, its own endpoints, and its own labeled population. That separation is why insurance coverage often follows the brand rather than the ingredient, and why a plan may authorize one semaglutide product and decline the other for the same person.

What the Weight-Management Evidence Actually Shows

The obesity program was built to answer a weight question directly. In STEP 1, 1,961 adults with obesity, or overweight with at least one weight-related condition and without diabetes, were randomized to 68 weeks of once-weekly semaglutide 2.4 mg or placebo alongside lifestyle intervention. Mean body weight change at week 68 was −14.9% with semaglutide versus −2.4% with placebo. Weight reductions of at least 5% were reached by 86.4% of the semaglutide group versus 31.5% on placebo, at least 10% by 69.1% versus 12.0%, and at least 15% by 50.5% versus 4.9%.

A higher dose was studied later. STEP UP randomized 1,407 adults with a BMI of 30 or above and without diabetes to 72 weeks of semaglutide 7.2 mg, 2.4 mg, or placebo. Mean weight change was −18.7% at 7.2 mg, −15.6% at 2.4 mg, and −3.9% with placebo. Gastrointestinal adverse events were more common at the higher dose, reported in 70.8% at 7.2 mg versus 61.2% at 2.4 mg and 42.8% on placebo.

Oral Versus Injectable: What Genuinely Differs

Route changes pharmacokinetics, not identity. Semaglutide is a peptide, and peptides are poorly absorbed from the gastrointestinal tract, which is why oral formulations use an absorption enhancer and why the tablet strengths do not map onto injection strengths. Injectable semaglutide is administered once weekly; oral semaglutide is taken daily.

Practical differences follow from that. A daily tablet asks for daily consistency; a weekly injection asks for one scheduled act. Tablets involve no needles, no sharps disposal, and no refrigeration considerations, while injections avoid the food and fluid timing conditions that oral semaglutide absorption depends on. Which trade-off suits you is a conversation for your prescriber, and the specific instructions for whichever product you are given come from your pharmacy label — not from an article.

Where Compounded Semaglutide Fits

Compounded semaglutide is a third category and should not be confused with either brand. The FDA is explicit that compounded drugs are not FDA approved, meaning the agency does not review them for safety, effectiveness, or quality before they are marketed. A compounded preparation is made by a licensed pharmacy pursuant to a prescription for an individual patient.

It is also not a generic version of anything. Ozempic and Wegovy have no approved generic equivalents, so any description of a compounded product as a generic misstates both its regulatory status and the evidence behind it. The FDA has separately warned companies selling unapproved semaglutide, tirzepatide, or retatrutide products falsely labeled "for research purposes" or "not for human consumption" — those are not compounded medicines and are not lawfully marketed drugs at all.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic a tablet or an injection?

Both. Ozempic began as a once-weekly subcutaneous injection supplied in multi-dose pens and prefilled single-dose syringes. There is now also an Ozempic tablet, covered by the shared FDA labeling for RYBELSUS and OZEMPIC tablets, in 1.5 mg, 4 mg, and 9 mg strengths. The two dosage forms are not interchangeable, because oral and injected semaglutide are absorbed very differently.

Is Ozempic approved by the FDA for weight loss?

No. The Ozempic injection is indicated to improve glycemic control in adults with type 2 diabetes, to reduce major adverse cardiovascular event risk in type 2 diabetes with established cardiovascular disease, and to slow kidney outcomes in type 2 diabetes with chronic kidney disease. The tablet labeling covers glycemic control and cardiovascular risk reduction. Neither label contains a weight-management indication.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide, but they are separate products with separate FDA applications and labeling. Ozempic is a type 2 diabetes medication. Wegovy is indicated for chronic weight management, for cardiovascular risk reduction in adults with established cardiovascular disease plus obesity or overweight, and for noncirrhotic MASH with moderate to advanced fibrosis. Wegovy is available as an injection and as tablets.

How much weight did people lose in the semaglutide obesity trials?

In STEP 1, which ran 68 weeks in 1,961 adults without diabetes, mean body weight change was −14.9% with semaglutide 2.4 mg versus −2.4% with placebo, and 50.5% of the semaglutide group lost at least 15% of body weight. In the later STEP UP trial, 72 weeks of semaglutide 7.2 mg produced a mean change of −18.7% versus −15.6% at 2.4 mg and −3.9% on placebo.

Is compounded semaglutide the same as Ozempic?

No. The FDA states that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness, or quality before they are marketed. A compounded preparation is made by a licensed pharmacy pursuant to a prescription for an individual patient. It is not a generic version of Ozempic or Wegovy, because neither brand has an approved generic equivalent.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.